Pronunciation:
mye-ra-beg-ron
Trade Name(s)
Ther. Class.
urinary tract antispasmodics
Pharm. Class.
beta-adrenergic agonists
Therapeutic Effect(s):
Absorption: 29–35% absorbed following oral administration.
Distribution: Widely distributed.
Metabolism and Excretion: Extensively metabolized, 6% excreted unchanged in urine (25 mg dose), remainder excreted in urine and feces as metabolites.
Half-life: Adults: 50 hr; Children: 26–31 hr.
TIME/ACTION PROFILE (effects on bladder)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 3–4 hr† | 24 hr |
Contraindicated in:
Use Cautiously in:
CV: ↑ BP, tachycardia
EENT: nasopharyngitis
GI: constipation, diarrhea, nausea
GU: urinary tract infection
Neuro: dizziness, headache
Misc: ANGIOEDEMA
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Drug-Drug
The extended-release tablets and extended-release oral suspension are NOT interchangeable and should NOT be combined.
Overactive Bladder
PO (Adults): 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk.
Renal Impairment
PO (Adults): eGFR 15–29 mL/min/m2 : 25 mg once daily (max dose = 25 mg/day).
Hepatic Impairment
PO (Adults): Moderate hepatic impairment: 25 mg once daily (max dose = 25 mg/day).
Neurogenic Detrusor Overactivity
PO (Children ≥3 yr and ≥35 kg): Extended-release tablets: 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk. Extended-release oral suspension (granules): 48 mg once daily; may ↑ to 80 mg once daily, if needed after 4–8 wk.
PO (Children ≥3 yr and 22–<35 kg): Extended-release oral suspension (granules): 32 mg once daily; may ↑ to 64 mg once daily, if needed after 4–8 wk.
PO (Children ≥3 yr and 11–<22 kg): Extended-release oral suspension (granules): 24 mg once daily; may ↑ to 48 mg once daily, if needed after 4–8 wk.
Renal Impairment
PO (Children ≥3 yr and ≥35 kg): eGFR 15–29 mL/min/m2 : Extended–release tablets: 25 mg once daily (max dose = 25 mg/day); Extended-release oral suspension (granules): 48 mg once daily (max dose = 48 mg/day).
Renal Impairment
PO (Children ≥3 yr and 22–<35 kg): eGFR 15–29 mL/min/m2 : Extended–release oral suspension (granules): 32 mg once daily (max dose = 32 mg/day).
Renal Impairment
PO (Children ≥3 yr and 11–<22 kg): eGFR 15–29 mL/min/m2 : Extended–release oral suspension (granules): 24 mg once daily (max dose = 24 mg/day).
Hepatic Impairment
PO (Children ≥3 yr and ≥35 kg): Moderate hepatic impairment: Extended–release tablets: 25 mg once daily (max dose = 25 mg/day); Extended-release oral suspension (granules): 48 mg once daily (max dose = 48 mg/day).
Hepatic Impairment
PO (Children ≥3 yr and 22–<35 kg): Moderate hepatic impairment: Extended–release oral suspension (granules): 32 mg once daily (max dose = 32 mg/day).
Hepatic Impairment
PO (Children ≥3 yr and 11–<22 kg): Moderate hepatic impairment: Extended–release oral suspension (granules): 24 mg once daily (max dose = 24 mg/day).
Extended-release tablets: 25 mg, 50 mg
Extended-release oral suspension (granules): 8 mg/mL
Monitor for signs and symptoms of angioedema (swelling of face, lips, tongue and/or larynx). Discontinue mirabegron and treat symptomatically.
Overactive Bladder
Neurogenic Detrusor Overactivity
Pediatric patients weighing ≥35 kg may use tablets or granules. Administer as an extended-release oral suspension once daily.
Decreased urinary frequency, urgency, and urge incontinence.